EUCTR2012-003126-25-GB进行中（未招募）1 期
An Open-Label, First-in-Human Study of the Safety, Tolerability, andPharmacokinetics of VX-970/M6620 in Combination With CytotoxicChemotherapy in Participants With Advanced Solid Tumors - MS201923-0001
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Merck KGaA
- 入组人数
- 195
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who meet all of the following inclusion criteria will be eligible for this study:
- •1.Male and female subjects =18 years of age
- •2.Disease status
- •Parts A and B/B2: Histologically or cytologically confirmed advanced solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective, or for whom regimens containing gemcitabine, cisplatin, and/or etoposide might be considered, and with measurable disease according to RECIST criteria (Version 1.1)
- •Pre-screening: subjects who are not current candidates for study drug treatment or do not elect to be candidates at this time, but may be candidates in the future:
- •a.Advanced (metastatic or locally-advanced unresectable and not eligible for definitive treatment, e.g., surgery/radiotherapy) histologically confirmed NSCLC
- •b.Available historical tumor specimen available for shipment to the sponsor as confirmed by the investigator unless otherwise agreed to by the sponsor or willing to provide a tumor biopsy (core) if the biopsy may be considered as part of standard clinical practice for the patient
- •c.Received or did not tolerate standard approved targeted therapy, if appropriate for tumor genotype (e.g., targeted therapies for ALK rearrangement or EGFR activating mutations)
- •Screening: subjects who are current candidates for study drug treatment:
- •a.Measurable disease according to RECIST criteria (Version 1.1)
- •b.Meet inclusion criteria a through c for Part C1 pre-screening.
- •a.Advanced (locally-advanced incurable or metastatic), histologically confirmed estrogen receptor, progesterone receptor, and HER2 negative breast cancer
- •b.Adequate available historical tumor specimen (core biopsy or surgical specimen; fine needle aspirate inadequate) available for shipment to the sponsor as confirmed by the investigator unless otherwise agreed to by the sponsor, or willing to provide a tumor biopsy (core) if the biopsy may be considered as part of standard clinical practice for the patient
- •c.Measurable disease according to RECIST criteria (Version 1.1)
- •a.Advanced (locally-advanced incurable or metastatic), histologically confirmed SCLC that is platinum-resistant, defined as disease progression during initial treatment with a platinum-based regimen or progression within 90 days of completion of platinum therapy. Subjects with platinum-resistant disease may receive a second-line non-platinum-based chemotherapy and subsequently be enrolled to this study. Subjects who received and are resistant to a second-line platinum-based chemotherapy, (i.e., progressing on or within 90 days of treatment with a platinum-based regimen) may also be enrolled into the study.
- •b. Adequate available historical tumor specimen if available (core biopsy or surgical specimen; fine needle aspirate inadequate) or willing to provide a tumor biopsy (core) if the biopsy may be considered as part of standard clinical practice for the patient. If a historical sample is unavailable, a subject may be enrolled at the discretion of the investigator and sponsor.
- •c. Measurable disease according to RECIST criteria (Version 1.1)
- •3.WHO performance status of 0 or 1
- •4.Life expectancy of =12 weeks
- •5.Hematological and biochemical indices within the ranges shown below at screening. No clinically significant change in these values must be confirmed on the first day of dosing, before study drug administration.
- •a.Hemoglobin: =8.0 g/dL
- •b.Absolute neutrophi
排除标准
- •1.Radiotherapy (except for palliative reasons) endocrine therapy, immunotherapy, or chemotherapy during the previous 4 weeks (6 weeks for nitrosoureas and Mitomycin C, and 4 weeks for investigational medicinal products) or less than 4 drug half-lives.
- •2.Prior chemotherapy
- •Parts A and B/B2:
- •Greater than 6 cycles of prior treatment with cisplatin and/or carboplatin, unless discussed with and approved by Vertex medical monitor.
- •Subjects with a known history of Grade 4 thrombocytopenia or Grade 4 neutropenia while receiving prior therapy, unless discussed with and approved by Vertex medical monitor.
- •a.Any cytotoxic chemotherapy beyond 1 line of platinum-based chemotherapy. One additional line of non-platinum based therapy in the advanced setting is allowed.
- •b.Any prior gemcitabine for the treatment of NSCLC in any setting within 6 months
- •a.Any prior platinum therapy in the adjuvant or neoadjuvant within 6 months of screening
- •b.Relapse within 3 months of completion of prior adjuvant or neoadjuvant chemotherapy
- •c.Any prior chemotherapy in the metastatic setting except a taxane and/or an anthracycline and 1 other non-platinium-based chemotherapy in the first- and second-line metastatic setting
- •a. Prior platinum-sensitive subjects, unless they progress on or within 90 days of completion of platinum-based regimen
- •b. There is no restriction on prior immunotherapy or targeted therapy in the metastatic setting unless combined together with a cytotoxic agent
- •c. During prior carboplatin therapy, requirement for dose reduction below AUC 5 mg.min/mL or discontinuation of carboplatin for toxicity or lack of tolerability. However, the subject would be eligible to receive cisplatin as long as otherwise meets criteria and is discussed with sponsor
- •3.Biomarkers
- •a. Subjects who are known to be TP53 wild-type, unless they are determined to have ATM loss of expression during screening or pre-screening or until all the planned subjects with TP53 mutation are enrolled as determined by the medical monitor
- •b. Subjects with unknown TP53 mutational status will be enrolled until the group of approximately 10 subjects without TP53 mutation or until all the planned subjects with TP53 mutation are enrolled as determined by the medical monitor
- •a.Subjects with known BRCA1/BRCA2 germline mutations, either determined and documented prior to Screening, or determined during Screening. Subjects with unknown BRCA1/BRCA2 status may be enrolled.
- •b.Subjects who are documented to be non-basaloid subtype using molecular profiling assay (e.g. PAM50 assay) prior to Screening
- •c.Subjects with unknown BRCA1/BRCA2 or basaloid subtype status will be enrolled until the number of enrolled subjects is approximately 40. If approximately 40 subjects have been enrolled and a minimum of 30 subjects who are basaloid positive and BRCA1/BRCA2 germline wild-type have not been enrolled, the basaloid subtype and BRCA status assay will be required at Screening to exclude subjects who are basaloid negative or have BRCA1/BRCA2 germline mutations.
- •4.Unresolved toxicity of CTCAE Grade 2 or greater from previous anti-cancer therapy or radiotherapy, excluding:
- •a.Alopecia, anemia or leukopenia or other toxicities that in the opinion of the investigator and the sponsor should not exclude the subject
- •5.History of spinal cord compression or brain metastases. Any history of leptomeningeal metastases.
- •6.Female subjects who are already pregnant or lactating, or plan
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate QR-421a in subjects with retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A GeneEUCTR2018-002433-38-FRProQR Therapeutics18
已完成
1 期
A Phase 1, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of SM07883, a Novel DYRK1a Inhibitor, Following Oral Administration to Healthy SubjectsNeurological - Alzheimer's diseaseAlzheimer's DiseaseACTRN12619000327189Samumed Pacific Pty Ltd28
已完成
不适用
A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of DNL104 in Healthy Subjects10029317Amyotrophic Lateral Sclerosis (ALS)NL-OMON42834Denali Therapeutics48
招募中
不适用
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons with Early Alzheimer's DiseasedementiaNL-OMON56092ImmunoBrain Checkpoint, Inc6
已完成
不适用
A first-in-human study to evaluate the safety and performance of placebo excipient-coated high-density microarray patches applied by an integrated application device.VaccinationsPublic Health - Other public healthACTRN12620000179932Vaxxas Pty Ltd43